TG Therapeutics

TG Therapeutics is a biopharmaceutical company focused on the acquisition, development, and commercialization of novel therapies for B-cell malignancies and autoimmune diseases. The company is currently developing two therapies targeting hematologic malignancies and autoimmune diseases. Ublituximab (TG-1101) is a novel glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B lymphocytes.